Menu
GWAS Study

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.

Cox DG, Curtit E, Romieu G et al.

27764800 PubMed ID
GWAS Study Type
3275 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

CD
Cox DG
CE
Curtit E
RG
Romieu G
FP
Fumoleau P
RM
Rios M
BH
Bonnefoi H
BT
Bachelot T
SP
Soulié P
JC
Jouannaud C
BH
Bourgeois H
PT
Petit T
TI
Tennevet I
AD
Assouline D
MM
Mathieu MC
JJ
Jacquin JP
LS
Lavau-Denes S
DA
Darut-Jouve A
FJ
Ferrero JM
TC
Tarpin C
LC
Lévy C
DV
Delecroix V
TV
Trillet-Lenoir V
CO
Cojocarasu O
MJ
Meunier J
PJ
Pierga JY
FC
Faure-Mercier C
BH
Blanché H
SM
Sahbatou M
BA
Boland A
BD
Bacq D
BC
Besse C
DJ
Deleuze JF
PI
Pauporté I
TG
Thomas G
PX
Pivot X
Chapter II

Abstract

Summary of the research findings

Genetic polymorphisms are associated with breast cancer risk. Clinical and epidemiological observations suggest that clinical characteristics of breast cancer, such as estrogen receptor or HER2 status, are also influenced by hereditary factors. To identify genetic variants associated with pathological characteristics of breast cancer patients, a Genome Wide Association Study was performed in a cohort of 9365 women from the French nationwide SIGNAL/PHARE studies (NCT00381901/RECF1098). Strong association between the FGFR2 locus and ER status of breast cancer patients was observed (ER-positive n=6211, ER-negative n=2516; rs3135718 OR=1.34 p=5.46×10-12). This association was limited to patients with HER2-negative tumors (ER-positive n=4267, ER-negative n=1185; rs3135724 OR=1.85 p=1.16×10-11). The FGFR2 locus is known to be associated with breast cancer risk. This study provides sound evidence for an association between variants in the FGFR2 locus and ER status among breast cancer patients, particularly among patients with HER2-negative disease. This refinement of the association between FGFR2 variants and ER-status to HER2-negative disease provides novel insight to potential biological and clinical influence of genetic polymorphisms on breast tumors.

1,944 French ancestry estrogen receptor positive cases, 1,331 French ancestry estrogen receptor negative cases

Chapter III

Study Statistics

Key metrics and study information

3275
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
France
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.